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Murine immunoglobulin G (IgG) plays an important role in mediating protective immune responses to
malaria. We still know relatively little about which IgG subclasses protect against this disease in mouse
models, although IgG2a and IgG2b are considered to be the most potent and dominate in successful pas-
sive transfer experiments in rodent malarias. To explore the mechanism(s) by which the different mouse
IgG subclasses may mediate a protective effect, we generated mouse IgG1, IgG2a, IgG2b and IgG3 speciﬁc
for the C-terminal 19-kDa region of Plasmodium falciparummerozoite surface protein 1 (PfMSP119), and to
the homologous antigen from Plasmodium yoelii (P. yoelii), both major targets of protective immune
responses. This panel of eight IgGs bound antigen with an afﬁnity comparable to that seen for their
epitope-matched parental monoclonal antibodies (mAbs) from which they were derived, although for
reasons of yield, we were only able to explore the function of mouse IgG1 recognizing PfMSP119 in detail,
both in vitro and in vivo. Murine IgG1 was as effective as the parental human IgG from which it was
derived at inducing NADPH-mediated oxidative bursts and degranulation from neutrophils. Despite
showing efﬁcacy in in vitro functional assays with neutrophils, the mouse IgG1 failed to protect against
parasite challenge in vivo. The lack of protection afforded by MSP119-speciﬁc IgG1 against parasite
challenge in wild type mice suggests that this Ab class does not play a major role in the control of
infection with mouse malaria in the Plasmodium berghei transgenic model.
 2012 Elsevier Inc. Open access under CC BY license.1. Introduction
Amongst mouse IgG subclasses, IgG2a and IgG2b are considered
to be themost potent activators, and dominate in successful passive
transfer experiments in both murine infection (including malaria),
and murine tumour models (Clynes et al., 2000; Nimmerjahn and
Ravetch, 2005; Spencer Valero et al., 1998). Such functional distinc-
tions have been attributed to differences in their capacity to ﬁx
complement and/or recruitment of relevant Fc-receptors for IgG
(FccRs) (Nimmerjahn and Ravetch, 2005). However, very few
studies have compared epitope-matched IgG subclasses in the
context of protection from both communicable and non-
communicable diseases (Chu et al., 2010; Giorgini et al., 2008;
Ishizaka et al., 1995; McLean et al., 2002; Reitan and Hannestad,l School of Tropical Medicine,
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 license.1995, 2002; Rodrigo et al., 2009; Torres et al., 2007), and in these
studies, disease-speciﬁc effects were observed between IgG
subclasses. For example, mouse IgG1 has been shown to be poor
at killing tumours, yet plays an important role in controlling gastro-
intestinal parasites (McCoy et al., 2008;Wojciechowski et al., 2009).
Mouse IgG1 is believed not to be a subclass associated with protec-
tive properties as it is not a potent complement activator and it
possesses an extremely low activation to inhibition (A:I) ratio (0.1
compared to 69 and 7 for IgG2a and IgG2b respectively), as a conse-
quence of its preference for binding the inhibitory FccRIIB receptor
(Woof, 2005). Work with non-epitope matched mouse monoclonal
antibodies (mAbs) targeting Plasmodium yoelii MSP119 has shown
conﬂicting data, with some IgG1 mAbs protecting from malaria
(e.g. mAb G3), and others (e.g. mAb B4), having little or no effect
on the course of disease (Spencer Valero et al., 1998). However, in
the absence of epitope-matched reagents, it is difﬁcult to directly
compare the efﬁcacy of IgG1 against the other subclasses in the
protection from blood-stage malaria. Due to structural and func-
tional differences between the murine IgG subclasses (in particular
with respect to FccRs they bind), and to attempt to resolve existing
controversies as to whether FcRs are indeed even required for
protection from malaria in the mouse, we generated two panels
C1     B10 
   IgG1            IgG2a                        IgG2b                            IgG3 
(a) (b)
Fig. 1. Generating two panels of epitope-matched murine IgG Abs speciﬁc for MSP119 epitopes C1 (P. falciparum-PfMSP119) or B10 (P. yoelii-PyMSP119). Diagram represents a
general overview to the construction of (a) C1 and (b) B10 mouse IgGs. Variable genes from parental mAbs C1 or B10 were sub-cloned into redesigned expression vectors for
each of the mouse IgG subclasses.
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tical epitopes on Plasmodium falciparum and P. yoeliiMSP119 (Fig. 1).
These were then used to investigate the anti-malarial properties of
the mouse subclasses in vivo.2. Materials and methods
2.1. Generation of PfMSP119-speciﬁc antibodies
2.1.1. Construction of pVL-C1-mouse kappa light chain
For all primer sequences, nucleotides in bold refer to restriction
enzyme sites whereas an underline highlights stop codons. The
plasmid pVL-C1-mouse kappa was generated by a three step PCR.
Primer pairs VL-C1for (50 GGC GTG CAC TCC GAT ATT GTG ATG
ACC CAG 30) and k-joint-rev (50 ggg aag atg gat aca gtt ggt gca
gca tca gtt c 30) were used to amplify the VL by PCR from
pVKExpress C1, whilst introducing an ApaL1 restriction site on
the 50 end. A second PCR with primer pairs k-joint-for (50 gaa ctg
atg ctg cac caa ctg tat cca tct tcc c 30) and MK-rev (50 gac tag tcc
ctc taa cac tca ttc ctg ttg a 30) containing a SpeI were used to ampli-
fy the mouse kappa light chain constant region from BALB/c geno-
mic DNA. Overlap PCR with primer pairs VL-C1for and MK-rev
were then used to fuse as a single PCR product the VL of C1 and
the mouse kappa constant region, which was then cloned in
pCR2.1-Topo (parking vector) prior to sub-cloning into the parental
pVKExpress C1 (McIntosh et al., 2007; Persic et al., 1997) as an
ApaLI/SpeI fragment.
2.1.2. Construction of pVH-C1-mIgG1
pVH-C1-IgA1 (Shi et al., 2011) was digested with SalI to remove
the IgA constant region sequence and re-ligated to produce
pVH-C1-delIgA1. This plasmid was then digested with BssHII/
XbaI to release the VH of C1 which was then sub-cloned into
pcDNA3.1-C1-hIgG1 from which the C1 and hIgG1 sequences werepreviously deleted (pcDNA3.1-delC1delIgG1) using the same
restriction sites to create pcDNA3.1-C1-delhIgG1. The murine
IgG1 constant region was ampliﬁed from BALB/c genomic DNA
using primer pairs Mg1-for (containing an XbaI site) (50 GCA AAA
GAG CGG CCT TCT AGA AGG TTT G 30) and Mg1-rev (50 CAC TGG
GAT CAT TTA CCA GGA GAG TG 30), and cloned into the parking
vector, prior to sub-cloning as an XbaI fragment into pcDNA3.1-
C1-delhIgG1 to generate pVH-C1-mIgG1.2.1.3. Construction of pVH-C1-mIgG2a
Primer pairs Mg2a-for (50 G GTC ACC ATC AAG AGG AGG AAG 30)
and Mg2a-rev (50 TCT AGA GCT CAT TTA CCC GGA GT 30) were used
to amplify the murine IgG2a from genomic DNA whilst introducing
a BstEII site 50 of the CH1 and an XbaI site 30 of the stop codon
respectively and cloned into the parking vector. pVH-C1-hIgG1
was digested with SalI and blunted with T4 DNA polymerase
(New England Biolabs) prior to recovery from gels, and digestion
with XbaI, into which a BstEII blunted/XbaI fragment from the
parking vector was ligated to create pVH-C1-mIgG2a.2.1.4. Construction of pVH-C1-mIgG2b and IgG3
Primer pairs Mg2b-for (50 GAT ATC GGT CAC AGT GCA AGC TCT
30) and Mg2b-rev (50TCT AGA GCT CAT TTA CCC GGA GA 30) were
used to amplify the murine IgG2b from genomic DNA whilst intro-
ducing an EcoRV site 50 of the CH1 and an XbaI site 30 of the stop
codon respectively and cloned into the parking vector. pVH-C1-
hIgG1 was digested with BamHI and blunted with T4 DNA poly-
merase (New England Biolabs) prior to recovery from gels, and
digestion with XbaI, into which an EcoRV blunted/XbaI fragment
from the parking vector was ligated to create pVH-C1-mIgG2b.
Primer pairs Mg3-for (50 GAT ATC GTT CAG GAT AGA GCT GGG
30) and Mg3-rev (50 TCT AGA TCT CAT TTA CCA GGG GA 30) were
used in the same way to generate pVH-C1-mIgG3.
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2.2.1. Construction of pVL-B10-mouse kappa light chain
pVL-C1-mouse kappa light chain was digested with ApaLI/XhoI
to release the VL of C1. The VL of B10 was subcloned as an ApaLI/
XhoI fragment derived from the parental expression vector
pB10-VL/10 (Pleass et al., 2003).
2.2.2. Construction of pVH-B10-mIgG2a
pVH-C1-mIgG2a and parental plasmid pB10-VH/5 (Pleass et al.,
2003) were digested with BssHII/BstEII to release the VH of C1
(pVH-delC1-mIgG2a) and the VH of B10 respectively. The VH of
B10 was sub-cloned into pVH-delC1-mIgG2a using the same
restriction sites and renamed pVH-B10-mIgG2a.
2.2.3. Construction of pVH-B10-mIgG1
The plasmid pVH-B10-mIgG1 was generated in two steps. pVH-
C1-mIgG1 and pVH-B10-mIgG2a were digested with BssHII/BstEII
to release the VH of C1 and VH of B10 respectively. The VH of
B10 was sub-cloned into pVH-delC1-mIgG1. Due to the presence
of a second BstEII site in exon 1 (CH1 domain) 160 bp after the
VH of B10 30 BstEII site, both plasmids were digested with BstEII
and the released fragment sub-cloned into pVH-B10delC1-mIgG1
with the same restriction sites to generate pVH-B10-mIgG1.
2.2.4. Construction of pVH-B10-mIgG2b and IgG3
pVH-B10-mIgG2a was partially digested with MfeI/XbaI to
release the IgG2a (pVH-B10-delmIgG2a) sequence after the VH of
B10. IgG2b and IgG3 were released from their respective parking
vectors with EcoRI/XbaI and sub-cloned into pVH-B10-delmIgG2a
compatible cohesive restriction site ends (MfeI–EcoRI) and XbaI.
The newly generated expression vectors were renamed as pVH-
B10-mIgG2b and pVH-B10-mIgG3. All plasmids were sequenced
in both directions to conﬁrm that no errors were introduced into
either the variable or constant region genes during PCR/cloning.
Amino acid translation of the VH and VL genes for both C1 and
B10 expressed in the mouse IgGs conﬁrmed that they are indeed
epitope-matched and are shown in Fig. 2.
2.3. Protein expression and puriﬁcation
Chinese hamster ovary (CHO)-K1 or human embryonic kidney
(HEK)-293T cells were transfected by electroporation withFig. 2. Sequencing of C1 and B10 VH and VL genes. Amino acid sequences alignment of
parental expression plasmids. (a) pVL-C1-mouse kappa compared with pVKExpress C1. (b
(c) pVL-B10-mouse kappa compared with pB10-VL/10. (d) IgG1, IgG2a, IgG2b, and IgG3corresponding heavy- and light-chain plasmids and the Abs were
expressed as follows: IgG1 on HEK-293T and IgG2a, IgG2b, and
IgG3 on CHO-K1. Positive clones secreting MSP119-speciﬁc IgG de-
tected by ELISA, on plates coated with recombinant PfMSP119-GST
(Burghaus and Holder, 1994) or PyMSP119-GST (Lewis, 1989), or
immuno-blotting using goat anti-mouse IgG-Fc (Pierce), goat
anti-mouse IgG1, IgG2a, IgG2b or IgG3 (Southern Biotech), or a
goat anti-mouse kappa (Southern Biotech) all conjugated to horse
radish peroxidase (HRP) as previously described (Pleass et al.,
2003). From large-scale cultures, mouse IgG was puriﬁed on HiTrap
protein G-Sepharose (GE Healthcare) by FPLC. The integrity and
purity of the antibodies were veriﬁed on 4–12% SDS–PAGE gradient
gels (Invitrogen).
2.4. Immunoﬂuorescence assay (IFA) and surface plasmon resonance
(SPR) analysis
For IFAs, washed erythrocytes from mice infected with the
transgenic (Tg) parasite Pb-PfM19 described by de Koning-Ward
and colleagues (2003), were ﬁxed on slides in methanol–acetone
(1:1, vol/vol) for 10 min. After being blocked in phosphate buffered
saline (PBS)/5% (vol/vol) goat serum, slides were incubated with
Abs at 5 lg ml1 in blocking buffer for 1 h, washed, then incubated
for 1 h with ﬂuorescein isothiocyanate (FITC)-conjugated goat
F(ab0)2 anti-human IgG (Sigma or Caltag) or goat anti-mouse IgG
c-chain speciﬁc (Southern Biotech) diluted 1:500 in blocking buf-
fer. After washing, slides were mounted with DAPI anti-fade and
Ab binding examined by IF microscopy on a Zeiss Axioscope 40
microscope. For SPR, quantitative association (KA) and dissociation
(KD) constants of the mouse IgG subclasses were measured using a
BIAcore X Machine (GE Healthcare). Antigen (PfMSP119-GST) at a
concentration of 50 lg/ml was amine-coupled onto a dextran
matrix CM5 sensor chip using a Pharmacia Biosensor Amine Cou-
pling Kit following the manufacturer’s instructions. Various con-
centrations of puriﬁed IgGs were then injected into a ﬁnal
volume of 50 lL at a rate of 10 lL/min over the chip and binding
kinetics analysed using BIAsimulation 3.0 software.
2.5. Luminol chemiluminescence assay of respiratory burst and
myeloperoxidase release
Neutrophils were isolated from heparinized blood taken from
healthy volunteers by the sedimentation of erythrocytes in 6%PfMSP119 and PyMSP119-binding epitope-matched mouse IgGs with the respective
) IgG1, IgG2a, IgG2b, and IgG3-C1 mouse IgG constructs compared with (h)IgG1-C1.
-B10 mouse IgG constructs compared with pB10-VH/5.
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30 min, followed by leucocyte separation on a discontinuous den-
sity gradient of Lymphoprep (q = 1.077 g/cm3; Nycomed,
Birmingham, UK) over Ficoll-Hypaque (q = 1.119 g/cm3), centri-
fuged at 700g for 20 min at room temperature. Approval for the
collection and use of human cells was obtained from the local
Queen’s Medical Centre ethics committee. Wells of chemilumines-
cence microtiter plates (Dynatech Laboratories, Billinghurst,
Sussex, UK) were coated with 150 ll of PfMSP119 at 5 lg ml1 in
coating buffer (0.1 M carbonate buffer, pH 9.6) and incubated
overnight at 4 C. After washing three times with PBS, 150 ll of
anti-PfMSP119 IgG at 100 or 50 lg ml1 was added to antigen
coated wells. In each case, triplicate wells were prepared and left
for 2 h at room temperature. After washing as before, 100 ll of
luminol [67 lg ml1 in Hank’s buffered saline solution (HBSS) con-
taining 20 mM HEPES and 0.1 g/100 ml globulin-free BSA (HBSS/
BSA)] was added to each well. After the addition of 50 ll of puriﬁed
neutrophils (106/ml in HBSS/BSA) to each well, plates were trans-
ferred to a Microlumat LB96P luminometer, and the chemilumi-
nescence was measured at 2 min intervals for 120 min at 37 C.
Data were analysed using Excel software.
2.6. Passive immunization and parasite challenge
Pathogen-free BALB/c mice from 6 to 8 weeks of age (caged
individually) were used to test in vivo efﬁcacy of mouse IgG1 in
passive transfer experiments. IgG1 was administered (0.5 mg/
injection) intraperitoneally (i.p.) on day 1, 0, and +1. Mice were
challenged with 5000 parasitized red blood cells (prbc) with
Pb-PfM19b that were administered i.p. 5 h after Ab injection onFig. 3. ELISA screening of PfMSP119 and PyMSP119-speciﬁc mouse IgGs. HEK-293T or
expression plasmids coding for the panel of mouse IgGs targeting P. falciparum or P. yoe
immunosorbent assay (ELISA). Five micrograms of recombinant puriﬁed antigen PfMSP11
IgG Fc-speciﬁc (HC) or anti-mouse kappa light chain (LC) secondary antibodies. To con
capture ELISA was performed. Plates were coated with goat anti-mouse F(ab0)2 and supe
All secondary reagents used were HRP conjugated and all plates were read at 450 nm. Bar
untransfected cells was used as negative control. Two micrograms of mAb B10 was useday 0. From day +2 mice were screened daily for weight loss and
% infected erythrocytes (parasitemia) counted by blood smears
stained with Giemsa (Sigma). At the end of the experiment or
when mice lost more than 20% of their initial weight, the animals
were humanely sacriﬁced. All animal experiments were approved
by the Home Ofﬁce and performed in accordance with UK
guidelines and regulations (PPL 40/2753).3. Results
3.1. Characterization of PfMSP119-speciﬁc mouse IgG1, IgG2a, IgG2b
and IgG3
PfMSP119 and PyMSP119-speciﬁc mouse IgG1, IgG2a, IgG2b and
IgG3 were secreted into culture supernatants from stably transfec-
ted CHO-K1 or HEK-293T cells. These recombinant antibodies
recognized either recombinant PfMSP119 or PyMSP119 by ELISAwith
polyclonal anti-mouse IgG Fc- or kappa light chain-speciﬁc second-
ary reagents (Fig. 3a and b). To check that each cell line only secreted
the intended antibody class, a second sandwich ELISA was devel-
oped to conﬁrm the subclass of the secreted IgG antibodies (Fig. 3c
and d). Here we focus on the PfMSP119-speciﬁc mouse IgG1, IgG2a,
IgG2b and IgG3 that were puriﬁed from CHO-K1 or HEK-293T
culture supernatants by protein-G afﬁnity-chromatography and
appearedpure by SDS–PAGEanalysis (Fig. 4a). Total yields of protein
after puriﬁcation, dialysis, and concentration fromnumerous differ-
ent batches of culture supernatant over several time points were in
the region of 15 mg from 30 l of supernatant for IgG1, and 2.8 mg,
2.1 mg, 1.5 mg from 7 l of supernatant for IgG2a, IgG2b and IgG3CHO-K1 mammalian cell lines were stably-transfected by electroporation with
lii MSP119. Clones secreting antigen-speciﬁc IgGs were detected by enzyme-linked
9 (a) or PyMSP119 (b) was coated and secreting clones detected with an anti-mouse
ﬁrm the secretion of the panel of C1 (c) or B10 (d) epitope-matched mouse IgGs a
rnatant from secreting clones analysed with subclass-speciﬁc secondary antibodies.
s represent the mean OD values from duplicate or triplicate wells. Supernatant from
d as positive control on panel b. Error bars represent Standard Deviation (SD).
Table 1
Association (KA) and dissociation (KD) rate constants for the mouse (m) and human (h)
IgG antibodies measured by SPR analysis.a
Antibody KA (1/M) KD (M)
mIgG1-C1 4.48  107 2.3  108
mIgG2a-C1 3.32  107 3.01  108
mIgG2b-C1 1.2  107 8.41  108
mIgG3-C1 2.33  107 3.11  108
hIgG1-C1 3.94  107 2.3  108
a Methodology described in McIntosh et al. (2007) and Pleass et al. (2003).
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likely a consequence of these subclasses being cloned into a differ-
ent expression plasmid (pVHExpress) compared to the mouse
IgG1 (pcDNA3.1), and therefore the majority of work described
focuses on IgG1 for which a sufﬁcient quantity of antibody was
derived for in vivo studies. The mouse IgG antibodies had an appar-
ent molecular weight (MW) of approximately 150 kDa, although
there were minor differences in the MW dependent on subclass.
All the preparations contained a signiﬁcant proportion of free heavy
and light chains (arrowed), suggesting that not all the expressed
protein folded into intact heterodimeric antibody. Western blotting
with the IgG subclass-speciﬁc reagents used in the detecting ELISAs
were unable to detect any of the mouse IgGs by immunoblotting on
both non-reducing and reducing gels, although an alternative poly-
clonal goat anti-mouse IgG-Fc did recognize mouse IgG1, IgG2a and
very faintly IgG2b (Fig. 4b). No signiﬁcant binding to mouse IgG3
was observed with this reagent despite the presence of an equiva-
lent amount of protein. Importantly, surface plasmon resonance
(SPR) analysis for all the IgG subclasses generated revealed no
reduction in afﬁnity for PfMSP119 when comparedwith the parental
human IgG1 antibody (Table 1 and Fig. 5), the binding constants
remaining essentially the same for each subclass. The recombinant
mouse IgG1 by indirect IFA produced a characteristic pattern of
MSP1 reactivity from P. falciparum infected erythrocytes (not
shown) and Plasmodium berghei parasites Tg for PfMSP119 (Fig. 6,
bottom right corner, arrowed).Fig. 4. Characterization of puriﬁed recombinant PfMSP119-speciﬁc epitope-
matched mouse IgGs. Characterization of the puriﬁed PfMSP119-speciﬁc mouse
IgGs. KEY: IgG1 (A), IgG2a, (B), IgG2b (C), IgG3 (D). (a) Five micrograms of each Ab
was run on NuPAGE 4–12% Bis–Tris SDS gels (Invitrogen) under denaturing non-
reducing conditions (A–D) or denaturing reducing conditions (E–H) and compared
with the control antibody human IgG1 (JS1) from which they were derived (IDEM).
An expected MW of 150 kDa for the intact antibodies was shown (arrowed, ‘IgG’)
although free constitutive heavy chains and light chain were observed (50 and
25 kDa respectively, arrowed). (b) Western Blot analysis of the IgG samples
transferred into PVDF membranes. Analysis was made following the same
conditions and sample order described on (a). Murine IgG1, IgG2a-C1 antibodies
were clearly detectable with polyclonal anti-mouse IgG Fc-speciﬁc secondary
antibody compared to IgG2b which was detected very faintly, but none of them
with the subclass-speciﬁc secondary antibodies used in ELISA.3.2. IgG1 triggers PfMSP119-speciﬁc neutrophil nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase activation through FccR
cross-linking
We next assessed the ability of the mouse IgG1 to interact with
FccRs and induce NADPH oxidase activation (respiratory burst)
and degranulation in blood neutrophils (Fig. 7). For neutrophils,
luminol chemiluminescence provides a read out of NADPH oxidase
activation and myeloperoxidase release (Pleass et al., 2007, 2003).
When attached to PfMSP119-GST-coated plates, the mouse IgG1 in-
duced comparable respiratory bursts to the parental human IgG1
(Fig. 7), suggesting that binding to PfMSP119 allows mouse IgG1
to be presented to neutrophil FccRs in an optimal conﬁguration
for receptor cross-linking and triggering of functional responses.
This ﬁnding is similar to that reported previously with a different
mouse IgG1 (mAb 12.10) also recognizing PfMSP119 (Lazarou
et al., 2009). Since mouse IgG1 is known to bind to human FccRIIA
but not to FccRIII, the activation of these neutrophils most likely
occurs through binding to the former receptor (Pleass et al., 2003).
3.3. Passive transfer of mouse IgG1 into wild type mice has no effect on
the course of a rodent malaria infection
Despite binding PfMSP119 with high afﬁnity, passive transfer of
mouse IgG1 into WT BALB/c mice failed to protect seven out of
eight animals, in two separate experiments, from a challenge infec-
tion with blood-stage P. berghei parasites Tg for PfMSP119 (Fig. 8).
4. Discussion
Although we have previously shown that mice Tg for human
FcRs are very useful for investigating human antibody function
in vivo, particularly where there are no suitable animal models
for P. falciparum infection in humans (McIntosh et al., 2007; Shi
et al., 2011), an argument can be made that they are somewhat
contrived, and therefore should be compared in parallel experi-
ments in wild type models of murine malaria infection with
murine antibodies. Here we describe the construction of two
panels of mouse IgG1, IgG2a, IgG2b and IgG3 recognizing identical
epitopes in PfMSP119 or PyMSP119.
Plasmodium spp. merozoites attach to the surface of red blood
cells by means of different surface antigens; among these antigens
is MSP1 (Holder, 2009). This surface antigen is cleaved twice; the
ﬁrst cleavage takes place at schizogony followed by a second
cleavage to reveal PfMSP119 just prior to invasion (Blackman
et al., 1994; Morgan et al., 1999). This 19-kDa peptide is relatively
conserved with few polymorphic variants and has been described
as a major candidate for vaccine development (Pizarro et al.,
2003), and continues to be the subject of study for immune therapy
(Roussilhon et al., 2007).
These epitope-matched antibodies were generated by cloning
variable genes from mAbs previously shown to confer passive pro-
tection from rodent malarias (McIntosh et al., 2007; Spencer Valero
et al., 1998), into newly generated expression constructs contain-
ing mouse IgG1, IgG2a, IgG2b and IgG3 constant region genes
Fig. 5. Surface plasmon resonance (SPR)-derived association and dissociation curves of mouse IgGs binding to PfMSP119. SPR association (KA) and dissociation (KD) curves of
mouse IgG binding to recombinant puriﬁed antigen PfMSP119 amine-coupled and immobilized to a CM5 sensor chip. The antibodies were injected into ﬂow at ﬁve different
concentrations of 2 lM (red), 1 lM (green), 0.5 lM (cyan), 0.25 lM pink), and 0.125 lM (dark blue) at time 0 and replaced with buffer alone at the times indicated with
arrows. No binding was seen from any of the IgGs onto control Ag coated in ﬂow cell 2. Data are summarized in Table 1. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 6. Characterization of puriﬁed mouse IgG1-C1 by immunoﬂuorescence assay (IFA). Mouse IgG1 is reactive with MSP119 on methanol–acetone-ﬁxed smears of merozoites
and erythrocytes infected with rodent P. berghei Tg for P. falciparum MSP119 (Pb-PfM19). Top panel: mAbs 12.8 and 12.10 previously described and known not to bind to Pb-
PfM19 (Lazarou et al., 2009) and B10 anti-PyMSP119 as negative control (Spencer Valero et al., 1998). Bottom panel: Human IgG1-C1 (JS1) and human IgG1-e9 (JS2) as
previously described (McIntosh et al., 2007) and murine IgG1-C1 bind Pb-PfM19 infected erythrocytes. Binding was visualized by staining with a FITC-conjugated secondary
reagent with nuclei stained with DAPI and assessed by ﬂuorescent microscopy under 40 magniﬁcation.
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IgGs with the same expression plasmid (pcDNA3.1). However, due
to the presence of a BstEII site on the C-terminal site of the VH-C1
in the parental human expression plasmid, we could not ﬁnd asuitable enzyme site with which releases the human IgG1
sequence from the expression vector and subclones all the mouse
IgG sequences in. The approach taken to generate the IgG2a, IgG2b,
and IgG3-C1 Abs was to sub-clone in the murine sequences in an
Fig. 7. Mouse PfMSP119-speciﬁc IgG1 is functional. Neutrophil NADH oxidative bursts were measured by adding antibodies to a chemiluminescence plate coated with
recombinant puriﬁed antigen PfMSP119. Relative Light Units (RLU, arbitrary units of light produced/second) were calculated from triplicate wells using neutrophils as
previously described (McIntosh et al., 2007; Pleass et al., 2007, 2003). Each point in the graph represents the mean value of triplicate wells. RLU were measured for over
120 min after the IgGs were added to neutrophils at two different concentrations of 50 (4) or 100 (s) lg/ml of mIgG1-C1. The overall response was comparable to that
derived from human IgG1-C1 at the same concentrations (N, d 50 or 100 lg/ml respectively). An IgG2a-Fc fused to antigen (PfMSP119-IgG2a-Fc) was used as an internal
negative control ( , 50 or 100 lg/ml respectively).
Fig. 8. Passive transfer of mouse PfMSP119-speciﬁc IgG1 does not protect mice from infection. Groups of four BALB/c wild type littermates were injected i.p. with a total dose
of 1.5 mg of puriﬁed anti-P. falciparum mouse IgG1 (open symbols, groups 1 and 3) or with PBS-vehicle control (closed symbols, groups 2 and 4) and challenged with 5000
parasitized red blood cells (prbc) derived from ‘passage’ animals infected with Pb-PfM19. Similar results were obtained from two independent experiments (a–b and c–d
respectively). (a) and (c) Mean weight as % of initial (mean weight from days 1, 0, +1) was assessed daily to determine if an animal had lost more than 20% of its original
weight (dotted line) used as a humane end-point in accordance with Home Ofﬁce regulations. (c) and (d) Seven out of eight animals treated with mIgG1-C1 succumbed to
malaria infection and no signiﬁcant difference was shown between the test and control groups. The percentage of parasitemia between the test and control groups was
similar in both experiments.
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expression of anti-malarial Abs (McIntosh et al., 2007). These
plasmids were expressed in CHO-K1 or HEK-293T cells, and all
eight secreted antibodies generated were shown to bind their
respective MSP119 antigen, and were identiﬁed as belonging to
the correct subclass by ELISA (Fig. 2).CHO and HEK-293 mammalian cell lines are widely used in the
production of recombinant proteins (Wurm, 2004). Predominantly
in industry, CHOs have been used to express a wide range of re-
combinant proteins including antibodies used in the treatment of
numerous diseases, including: multiple sclerosis, arthritis and
cancer (Hossler et al., 2009; Kelley, 2009). To a lesser extent,
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nant antibodies, but alongside CHOs, they have been the subject of
study for increased productivity in the ﬁeld (Wurm, 2004).
HEK-293s have been used to express recombinant proteins for
studies in neurology, electrophysiology and to produce mAbs
amongst other therapeutic proteins (Chen et al., 2011; Thomas
and Smart, 2005). Functional IgGs need to be glycosylated in their
Fc-fragment in order to have Fc-mediated effector functions
(Jefferis, 2005; Walsh and Jefferis, 2006), although we have not
directly assessed the glycosylation status of these reagents, CHO
and HEK-293 cell lines have been previously shown to effectively
secrete Abs with N-linked carbohydrates (Schlenke et al., 2007;
Sethuraman and Stadheim, 2006).
The mouse IgG1, IgG2a, IgG2b and IgG3 all bound PfMSP119
with high afﬁnity as determined by surface plasmon resonance
analysis (Fig. 4). The panel of IgG antibodies bound with compara-
ble afﬁnity to recombinant PfMSP119 in line with previous observa-
tions with other antibodies (McIntosh et al., 2007), and the mouse
IgG1 bound to native protein as determined by immunoﬂuores-
cence microscopy with infected erythrocytes (Fig. 6). Previous
results have shown that the parental human IgG1 from which
these mouse antibodies were derived is dependent on FcR-
mediated recruitment for function, and that inhibition of erythro-
cyte invasion and/or inhibition of MSP1 processing are/is not the
principal mechanism through which this antibody controls
parasites (McIntosh et al., 2007).
Typically in passive transfer experiments with rodent malarias,
large concentrations of antibody (1.5 mg total dose per mouse,
given as three individual doses) have to be given to provide protec-
tion. Although we could produce sufﬁcient quantities of all the
antibody classes to allow for preliminary in vitro comparisons to
be made, we could only generate sufﬁcient mIgG1 with which to
do in vivo work. Intriguingly, passive transfer experiments with
this IgG1 antibody failed to protect BALB/c mice from challenge
infection with malaria parasites (Fig. 8). Although the mouse
IgG1 was fully functional, as determined by its ability to induce
NADPH mediated oxidative bursts from human neutrophils, the
antibody was ineffective at controlling the development of malaria
when passively transferred into BALB/c mice that were challenged
with the Tg parasite Pb-PfM19 (de Koning-Ward et al., 2003). In
contrast to mouse IgG2a or IgG2b, mouse IgG1 binds preferentially
to inhibitory FccRIIB (CD32B) expressed on murine macrophages,
monocytes and B cells (Nimmerjahn and Ravetch, 2006; Pleass
and Woof, 2001), but not on neutrophils, offering a possible
explanation as to why this subclass was found to be ineffective
at controlling the development of a lethal malaria infection when
passively transferred into recipient mice.
The similarities of the genomes of the human and rodent
Plasmodium spp. with their 14 chromosomes, ranging from 23 to
27 Mb, coding for over 5000 proteins from which around 80% of
the +5300 genes found in these genomes are orthologous, highlight
the importance of murine malarias as models to understand the
human disease (Doolan, 2011; Hall et al., 2005; Janse et al.,
2010). These genetic similarities have led to the development of
targeted gene knock-outs, mutations, ﬂuorescently-tagged, gener-
ation of ‘reporter’ or ‘attenuated’ parasites that contribute to the
development of reliable vaccines against the disease (Janse et al.,
2010). To date, 561 rodent parasite mutants (predominantly
P. berghei) have been reported (Rodent Malaria genetically
modiﬁed Parasites DataBase (RMgmDB) http://www.pberghei.eu/
accessed on 11th August 2011).
The use of Tg P. berghei rodent parasites expressing vaccine-
candidate Ags from orthologous genes of P. falciparum has been
described for a wide range of proteins and genes, such as the:
sporozoite adhesive protein TRAP (Wengelnik et al., 1999),
circumsporozoite protein (CSP) (Persson et al., 2002; Tewariet al., 2002), the chloroquine resistance transporter (CRT) (Ecker
et al., 2011), and the UIS4 and HT1 genes that code for a parasi-
tophorous vacuole membrane protein in sporozoites and liver
stages (expressed in a Tg P. yoelii) and a hexose transporter,
respectively (Blume et al., 2011; Mackellar et al., 2010).
Parasites Tg for MSP119 are no exception. Rodent parasite
Plasmodium chabaudi MSP119 has been expressed in P. falciparum
and used for in vitro studies (Corran et al., 2004), and two Tg rodent
P. berghei parasites expressing PfMSP119 have been described:
Pb-PfM19 and PfMSP1–19Pb8.7 (Cao et al., 2009; de Koning-Ward
et al., 2003) (respectively). Passive immunization of human IgG1
anti-PfMSP119 in BALB/c mice challenged and infected with Pb-
PfM19, protected CD64-Tg mice (but not WT mice) from the course
of infection (McIntosh et al., 2007). Similar results were found in
mice immunized with puriﬁed rabbit anti-PfMSP142 IgG where
sterile protection was also observed (Sachdeva et al., 2006). How-
ever, alternatively from these experiments, passive transfer of Abs
12.8 and 12.10 into BALB/c mice challenged with Pb-PfM19 con-
ﬁrmed their inability to protect in vivo suggesting that the pres-
ence of six amino acids of P. berghei’s MSP119 in the Tg parasite
was required for both mAbs to be able to bind to the PfMSP119 epi-
tope (Lazarou et al., 2009). These discrepant results from passive
transfer experiments in infections with Pb-PfM19 have encouraged
us to assess the efﬁcacy of the alternate panel of IgGs targeting
PyMSP119 to elucidate their response in a more natural model of
infection.
From 1965 to 2010, more than 1900 immunization studies have
been conducted involving all four rodent Plasmodium spp. and hu-
man parasites in feasible vaccine development trials. In this vast
amount of time and research, many combinations of treatments
have been studied such as: (1) immunizations with live, attenuated
or dead parasites, (2) puriﬁed proteins such as Ags, Abs, DNA sub-
units, via multiple routes of delivery (Guilbride et al., 2010). Pas-
sive transfer experiments in vivo looking at the efﬁcacy of Abs in
controlling malaria continue to be of interest as still, the mecha-
nisms of action of the Fc-portion of Abs in controlling the disease
is not completely understood. Current improvements in the mass
production of recombinant proteins could allow IgG therapies to
become the standard choice of treatment against blood-stage
malaria in the near future. It is of our interest to continue this
project and aim to increase the yield of puriﬁed Abs from transfec-
ted mammalian cell lines by expressing our panel of IgGs in Sp2/0
myelomas for instance. With greater yields of puriﬁed Abs,
we would be able to complete the in vitro characterization of the
remaining -C1 Abs and compare in vivo both panels of the
epitope-matched IgGs constructed.
In summary, two panels of epitope-matched mouse IgGs
(IgG1, IgG2a, IgG2b, and IgG3) targeting PfMSP119 or PyMSP119
were constructed and expressed in mammalian cell lines. A novel
PfMSP119-speciﬁc mouse IgG1 did not show protective capability
against parasite challenge in mice but was shown to be fully func-
tional in vitro. Whilst this ﬁnding may indicate that IgG1 does not
play a major role in protection against malaria, we cannot rule out
the possibility that the ﬁndings reﬂect certain shortcomings of the
PfMSP119 Tg P. berghei rodent malaria model used, hence future
work aims to investigate the role of the other IgG subclasses
generated using the anti-P. yoelii panel of antibodies described
herein.
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